Can FDG-PET be used to predict growth of stage I lung cancer?

M. Tann, Kumar Sandrasegaran, H. T. Winer-Muram, S. G. Jennings, M. E. Welling, James Fletcher

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim: To determine the relationship between the metabolic activity measured by 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) and computed tomography (CT)-derived tumour growth rates for stage 1 lung cancer. Methods: Stage I lung cancer patients at our institution who underwent FDG PET, and who had at least two pre-treatment chest CT examinations (n = 51), were retrospectively identified. Metabolic activity was defined by maximum lesion standardized uptake value (SUV) and maximum lesion-to-mean background activity (LBR). Growth rates were determined from serial CT volume measurements and the doubling time (DT) was calculated. Tumour growth rates were divided into rapid (DT < 180 days), intermediate (DT = 180-270 days), and slow (DT > 270 days) groups. Results: Rapid, moderate, and slow DT were seen in 22, 19, and 10 patients, respectively. Means (standard deviations) of SUV in the three groups (from rapid to slow growth rate) were 8.2 (4.8), 5.5 (4.5), and 2.2 (1.1), respectively and of LBR were 22.7 (10.1), 15.1 (12.6), and 6 (2.6), respectively. There was a significant relationship between SUV and DT (p < 0.05), as well as between LBR and DT (p < 0.05). Conclusions: For stage I lung tumours, there is a significant relationship between growth rates, as measured by serial CT examinations, and the initial pre-treatment metabolic activities, as measured by FDG uptake. This suggests that in patients in whom it is difficult to decide on the aggressiveness on treatment, FDG-PET may be used as additional prognostic tool for determining management.

Original languageEnglish
Pages (from-to)856-863
Number of pages8
JournalClinical Radiology
Volume63
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Positron-Emission Tomography
Lung Neoplasms
Glucose
Growth
Tomography
Neoplasms
Cone-Beam Computed Tomography
Thorax
Therapeutics
Lung

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Can FDG-PET be used to predict growth of stage I lung cancer? / Tann, M.; Sandrasegaran, Kumar; Winer-Muram, H. T.; Jennings, S. G.; Welling, M. E.; Fletcher, James.

In: Clinical Radiology, Vol. 63, No. 8, 08.2008, p. 856-863.

Research output: Contribution to journalArticle

Tann, M. ; Sandrasegaran, Kumar ; Winer-Muram, H. T. ; Jennings, S. G. ; Welling, M. E. ; Fletcher, James. / Can FDG-PET be used to predict growth of stage I lung cancer?. In: Clinical Radiology. 2008 ; Vol. 63, No. 8. pp. 856-863.
@article{0d34793394d14186a2567f9729ed6fc3,
title = "Can FDG-PET be used to predict growth of stage I lung cancer?",
abstract = "Aim: To determine the relationship between the metabolic activity measured by 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) and computed tomography (CT)-derived tumour growth rates for stage 1 lung cancer. Methods: Stage I lung cancer patients at our institution who underwent FDG PET, and who had at least two pre-treatment chest CT examinations (n = 51), were retrospectively identified. Metabolic activity was defined by maximum lesion standardized uptake value (SUV) and maximum lesion-to-mean background activity (LBR). Growth rates were determined from serial CT volume measurements and the doubling time (DT) was calculated. Tumour growth rates were divided into rapid (DT < 180 days), intermediate (DT = 180-270 days), and slow (DT > 270 days) groups. Results: Rapid, moderate, and slow DT were seen in 22, 19, and 10 patients, respectively. Means (standard deviations) of SUV in the three groups (from rapid to slow growth rate) were 8.2 (4.8), 5.5 (4.5), and 2.2 (1.1), respectively and of LBR were 22.7 (10.1), 15.1 (12.6), and 6 (2.6), respectively. There was a significant relationship between SUV and DT (p < 0.05), as well as between LBR and DT (p < 0.05). Conclusions: For stage I lung tumours, there is a significant relationship between growth rates, as measured by serial CT examinations, and the initial pre-treatment metabolic activities, as measured by FDG uptake. This suggests that in patients in whom it is difficult to decide on the aggressiveness on treatment, FDG-PET may be used as additional prognostic tool for determining management.",
author = "M. Tann and Kumar Sandrasegaran and Winer-Muram, {H. T.} and Jennings, {S. G.} and Welling, {M. E.} and James Fletcher",
year = "2008",
month = "8",
doi = "10.1016/j.crad.2008.01.012",
language = "English",
volume = "63",
pages = "856--863",
journal = "Clinical Radiology",
issn = "0009-9260",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Can FDG-PET be used to predict growth of stage I lung cancer?

AU - Tann, M.

AU - Sandrasegaran, Kumar

AU - Winer-Muram, H. T.

AU - Jennings, S. G.

AU - Welling, M. E.

AU - Fletcher, James

PY - 2008/8

Y1 - 2008/8

N2 - Aim: To determine the relationship between the metabolic activity measured by 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) and computed tomography (CT)-derived tumour growth rates for stage 1 lung cancer. Methods: Stage I lung cancer patients at our institution who underwent FDG PET, and who had at least two pre-treatment chest CT examinations (n = 51), were retrospectively identified. Metabolic activity was defined by maximum lesion standardized uptake value (SUV) and maximum lesion-to-mean background activity (LBR). Growth rates were determined from serial CT volume measurements and the doubling time (DT) was calculated. Tumour growth rates were divided into rapid (DT < 180 days), intermediate (DT = 180-270 days), and slow (DT > 270 days) groups. Results: Rapid, moderate, and slow DT were seen in 22, 19, and 10 patients, respectively. Means (standard deviations) of SUV in the three groups (from rapid to slow growth rate) were 8.2 (4.8), 5.5 (4.5), and 2.2 (1.1), respectively and of LBR were 22.7 (10.1), 15.1 (12.6), and 6 (2.6), respectively. There was a significant relationship between SUV and DT (p < 0.05), as well as between LBR and DT (p < 0.05). Conclusions: For stage I lung tumours, there is a significant relationship between growth rates, as measured by serial CT examinations, and the initial pre-treatment metabolic activities, as measured by FDG uptake. This suggests that in patients in whom it is difficult to decide on the aggressiveness on treatment, FDG-PET may be used as additional prognostic tool for determining management.

AB - Aim: To determine the relationship between the metabolic activity measured by 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) and computed tomography (CT)-derived tumour growth rates for stage 1 lung cancer. Methods: Stage I lung cancer patients at our institution who underwent FDG PET, and who had at least two pre-treatment chest CT examinations (n = 51), were retrospectively identified. Metabolic activity was defined by maximum lesion standardized uptake value (SUV) and maximum lesion-to-mean background activity (LBR). Growth rates were determined from serial CT volume measurements and the doubling time (DT) was calculated. Tumour growth rates were divided into rapid (DT < 180 days), intermediate (DT = 180-270 days), and slow (DT > 270 days) groups. Results: Rapid, moderate, and slow DT were seen in 22, 19, and 10 patients, respectively. Means (standard deviations) of SUV in the three groups (from rapid to slow growth rate) were 8.2 (4.8), 5.5 (4.5), and 2.2 (1.1), respectively and of LBR were 22.7 (10.1), 15.1 (12.6), and 6 (2.6), respectively. There was a significant relationship between SUV and DT (p < 0.05), as well as between LBR and DT (p < 0.05). Conclusions: For stage I lung tumours, there is a significant relationship between growth rates, as measured by serial CT examinations, and the initial pre-treatment metabolic activities, as measured by FDG uptake. This suggests that in patients in whom it is difficult to decide on the aggressiveness on treatment, FDG-PET may be used as additional prognostic tool for determining management.

UR - http://www.scopus.com/inward/record.url?scp=46749157885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749157885&partnerID=8YFLogxK

U2 - 10.1016/j.crad.2008.01.012

DO - 10.1016/j.crad.2008.01.012

M3 - Article

C2 - 18625349

AN - SCOPUS:46749157885

VL - 63

SP - 856

EP - 863

JO - Clinical Radiology

JF - Clinical Radiology

SN - 0009-9260

IS - 8

ER -